Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.52 |
| ▸ | CNR2 | P34972 | 14/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5208662 | 0.88 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL5147329 | 0.81 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL5146873 | 0.78 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL5145539 | 0.76 | CNR1 (0.71) | CNR1CNR2 | |
| SCHEMBL13113804 | 0.74 | ADRB2 (0.42) | CYP2C9 | |
| SCHEMBL5585096 | 0.74 | CNR1 (0.45) | CNR1CNR2CYP2C9 | |
| SCHEMBL13114070 | 0.74 | CNR1 (0.72) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL3372655 | 0.73 | ADRB2 (0.41) | CYP2C9 | |
| SCHEMBL5145391 | 0.72 | CNR2 (0.36) | CNR1CNR2CYP2C9 | |
| SCHEMBL13114076 | 0.72 | CNR1 (0.77) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663113-A4 | SUBSTITUTED SULFONAMIDES | MERCK & CO INC (US) | 2007-06-13 | — | — | EP | claimed |
| US-20070105914-A1 | Substituted sulfonamides | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | claimed |
| CN-1956949-A | Substituted sulfonamides | MERCK & CO INC (US) | 2007-05-02 | — | — | CN | claimed |
| EP-1663113-A2 | SUBSTITUTED SULFONAMIDES | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005027837-A2 | SUBSTITUTED SULFONAMIDES | MERCK & CO., INC. (US) | 2005-03-31 | — | — | WO | claimed |
| US-20070105914-A1 | Substituted sulfonamides | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | disclosed |
| US-20070105914-A1 | Substituted sulfonamides | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | disclosed |
| US-20070105914-A1 | Substituted sulfonamides | MERCK SHARP & DOHME CORP. | 2007-05-10 | — | — | US | disclosed |
| CN-1956949-A | Substituted sulfonamides | MERCK & CO INC (US) | 2007-05-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105914-A1 | Substituted sulfonamides | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885CYP2C9 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.